Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese


Forum Home Forum Home > General Discussion > General Discussion
  New Posts New Posts RSS Feed - FDA approves new flu drug
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Online Discussion: Tracking new emerging diseases and the next pandemic

FDA approves new flu drug

 Post Reply Post Reply
Author
Message
Technophobe View Drop Down
Senior Moderator
Senior Moderator
Avatar

Joined: January 16 2014
Location: Scotland
Status: Online
Points: 51235
Post Options Post Options   Thanks (0) Thanks(0)   Quote Technophobe Quote  Post ReplyReply Direct Link To This Post Topic: FDA approves new flu drug
    Posted: October 24 2018 at 2:22pm
FDA approves first new flu drug in nearly 20 years

By Susan Scutti, CNN

Updated 1758 GMT (0158 HKT) October 24, 2018

(CNN)Flu sufferers now have a new option for relieving symptoms. Xofluza (baloxavir marboxil), a single-dose, oral prescription drug, was approved by the US Food and Drug Administration on Wednesday. The antiviral is the first new flu treatment approved by the FDA in nearly 20 years, FDA Commissioner Dr. Scott Gottlieb said in a statement.

"With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical," said Gottlieb.

The pill is intended for patients who are 12 or older and who have had symptoms for no more than 48 hours. When patients with the flu, a respiratory illness, are treated within 48 hours of becoming sick, antiviral drugs can reduce symptoms and duration of illness, according to the FDA.

Two clinical trials with 1,832 patients proved the safety and efficacy of Xofluza when taken within 48 hours of experiencing flu symptoms, according to the FDA statement. In both experiments, the Xofluza patients' symptoms eased in a shorter amount of time compared to placebo patients. However, no difference in symptom duration was seen between patients who received Xofluza and those who received another flu drug.
The most common side effects of Xofluza included diarrhea and bronchitis, the government agency reported.

Xofluza was discovered by Japan's Shionogi & Co., Ltd. and was developed globally by Shionogi and the Roche Group, according to a statement from Roche. The drug was approved in February by the Japanese Ministry of Health, Labour and Welfare for the treatment of influenza types A and B in both adult and pediatric patients. Excluding Japan and Taiwan, Roche now holds worldwide rights to the drug.

Xofluza will be available across the US in the coming weeks, said Andrew Villani, senior manager, corporate relations, at Genentech, the US based distributor of the new drug. "The wholesale acquisition cost for Xofluza is $150, which is at parity with leading antiviral treatments, including Tamiflu." However, patients with commercial insurance that cover the cost of the drug and use a coupon available on a company website may pay as little as $30, he added.

While Gottlieb welcomed the addition of another drug to treat influenza, he stressed that no treatment is a replacement for the flu vaccine and urged anyone who has not done so to get a flu shot.

The US Centers for Disease Control and Prevention recommends getting the flu vaccine by the end of October. A variety of vaccines have been approved for the 2018-19 flu season, including nasal mist and other needleless options. Flu vaccines are widely available, including in doctor's offices, local pharmacies, some work places and even certain groceries stores.

The vaccine is imperfect and some people may still get sick even after getting a flu shot. However, those who get flu after receiving vaccine are less likely to require hospitalization and they're less likely to die, according to the CDC.

Source:   https://edition.cnn.com/2018/10/24/health/xofluza-approved-by-fda/index.html
Absence of proof is not proof of absence.
Back to Top
roni3470 View Drop Down
Senior Member
Senior Member
Avatar

Joined: August 30 2006
Location: Colorado
Status: Offline
Points: 1265
Post Options Post Options   Thanks (0) Thanks(0)   Quote roni3470 Quote  Post ReplyReply Direct Link To This Post Posted: October 24 2018 at 2:40pm
I have a bad feeling about this!
NOW is the Season to Know

that Everything you Do

is Sacred."
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down